Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tongji University | OTHER |
| Tsinghua University | OTHER |
Not provided
Not provided
Not provided
Not provided
The investigators propose to investigate the definition of hormone overdose and misuse (HODM) in Chinese transgender and gender nonconforming population (TGNCs), address the incidence of HODM in Chinese TGNC population, related factors and risks, identify the probable causes of HODM, and follow up HODM individuals to explore long-term effects.
The research questions are:
Q1 What is the definition and the criteria of HODM in Chinese TGNC population? Q2 What is the prevalence of HODM in Chinese TGNC population? Q3 What factors and risks are relevant to HODM? Q4 What are the causes? Q5 What are the long-term effects of HODM in Chinese TGNC population, compared to those who enroll in regular GAHT regimens?
The investigators decide to employ a mixed-methods design to construct a full research framework on HODM. A prospective cohort study is a component of the study.
The study can be divided into four stages to address research questions. Stage I will establish a precise definition and eligibility criteria of HODM through expert panel meeting and stakeholder engagement. Subsequently, a cross-sectional study will be conducted to evaluate the rate, subtypes, and related factors of HODM in Chinese TGNCs. In Stage III, semi-structured interviews and focus groups for TGNCs who are identified as HODM will be employed to investigate the causes, motivations and personal impact factors. This stage will be divided into two phases, Stage III-a before the cross-sectional study to provide a brief picture of HODM behaviors, and Stage III-b after the cross-sectional study to draw an overall pattern. Lastly, all participants of Stage II or III who would like to participate in our follow-up will be included in prospective cohorts to assess long-term effects.
Among the stages, the cohort study is the subject of the registration. The investigators propose two cohorts in the study. Participants who are identified as HODM will be assigned to cohort 1 [HODM cohort], and those who are identified as regular GAHT use will be assigned to cohort 2 [non-HODM cohort]. Participants will be asked to report their gender-related and hormone use-related conditions, and mental health-related conditions at specific timepoints. The investigators will compare the HODM cohort to the non-HODM cohort to see if the overall incidence of adverse effects, gender-related, hormone-related, and mental health-related conditions differ in the cohorts.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hormone Overdose and Misuse Group | Transgender and gender non-conforming individuals who have been identified as hormone overdose and misuse (HODM) at start of the cohorts according to the criteria established by the study. |
| |
| Non-Hormone Overdose and Misuse Group | Transgender and gender non-conforming individuals who have been identified as without hormone overdose or misuse (HODM) at start of the cohorts according to the criteria established by the study. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hormone Overdose and Misuse | Other | This is an observational study. Hormone Overdose and Misuse is an exposure. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 24 months from the baseline assessment |
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 60 months from the baseline assessment |
| Measure | Description | Time Frame |
|---|---|---|
| GAHT attrition | Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. | 24 months from the baseline assessment |
| GAHT attrition |
| Measure | Description | Time Frame |
|---|---|---|
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 1 month from the baseline assessment |
| Moderate-to-severe adverse events |
Inclusion Criteria:
Exclusion Criteria:
Only individuals who identified themselves as transgender female, transgender male, genderqueer, gender non-binary, crossdresser, or any other subgroups of Transgender and Gender Non-conforming population (TGNCs) will be recruited.
Not provided
We will disseminate a questionnaire among online TGNC communities, social medias, under the help of TGNC-related non-government organizations (NGO). Each participant will be asked to share the link to other TGNCs. Only the completers of the questionnaire who agree to be followed up will be eligible for the cohort study. However, if needed, we will also recruit more TGNCs from outside previous participants via social media.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ben-tuo Zeng | Contact | +86-18990938417 | zengbentuoxmu@outlook.com |
| Name | Affiliation | Role |
|---|---|---|
| Ben-tuo Zeng | School of Medicine, Xiamen University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| School of Medicine, Xiamen University | Xiamen | Fujian | 361102 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000068116 | Gender Dysphoria |
| D062787 | Drug Overdose |
| ID | Term |
|---|---|
| D020018 | Sexual Dysfunctions, Psychological |
| D001523 | Mental Disorders |
| D063487 | Prescription Drug Misuse |
| D000076064 | Drug Misuse |
Not provided
Not provided
Not provided
Not provided
Not provided
Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. |
| 60 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 24 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 60 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 12 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 24 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 36 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 60 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 12 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 24 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 36 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 60 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 24 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 60 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 24 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 60 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 24 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 60 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 12 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 24 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 36 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 24 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 60 months from the baseline assessment |
Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). |
| 3 months from the baseline assessment |
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 6 months from the baseline assessment |
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 12 months from the baseline assessment |
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 18 months from the baseline assessment |
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 30 months from the baseline assessment |
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 36 months from the baseline assessment |
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 42 months from the baseline assessment |
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 48 months from the baseline assessment |
| Moderate-to-severe adverse events | Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). | 54 months from the baseline assessment |
| GAHT attrition | Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. | 6 months from the baseline assessment |
| GAHT attrition | Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. | 12 months from the baseline assessment |
| GAHT attrition | Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. | 18 months from the baseline assessment |
| GAHT attrition | Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. | 30 months from the baseline assessment |
| GAHT attrition | Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. | 36 months from the baseline assessment |
| GAHT attrition | Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. | 42 months from the baseline assessment |
| GAHT attrition | Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. | 48 months from the baseline assessment |
| GAHT attrition | Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. | 54 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 3 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 6 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 12 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 18 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 30 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 36 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 42 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 48 months from the baseline assessment |
| Gender dysphoria | Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. | 54 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 1 month from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 3 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 6 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 18 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 30 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 42 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 48 months from the baseline assessment |
| Depression | Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. | 54 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 1 month from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 3 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 6 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 18 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 30 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 42 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 48 months from the baseline assessment |
| Anxiety | Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. | 54 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 6 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 12 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 18 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 30 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 36 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 42 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 48 months from the baseline assessment |
| General quality of life | Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. | 54 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 6 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 12 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 18 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 30 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 36 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 42 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 48 months from the baseline assessment |
| Body image | Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. | 54 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 3 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 6 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 12 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 18 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 30 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 36 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 42 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 48 months from the baseline assessment |
| Body-gender congruence | Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. | 54 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 3 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 6 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 18 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 30 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 42 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 48 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 54 months from the baseline assessment |
| Tanner stage | Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. | 60 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 3 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 6 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 12 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 18 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 30 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 36 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 42 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 48 months from the baseline assessment |
| Gender identity | Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. | 54 months from the baseline assessment |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |